Health Ministry evaluates global collaboration, local preparedness for Hepatitis Delta
Islamabad, Pakistan – Web Desk: The Ministry of Health, in a high-level meeting chaired by Federal Health Minister Mustafa Kamal, reviewed measures to combat the rapidly spreading Hepatitis D virus in Pakistan. Representatives from China’s leading pharmaceutical company Huahui Health participated in the session to brief officials on their innovative Hepatitis Delta therapy, HH-003.
HH-003 has recently completed successful Phase II international clinical trials and received approval in China for its safety and efficacy. The American Food and Drug Administration (FDA) has also recognized it as a breakthrough therapy.
During the meeting, the Health Ministry and DRAP discussed promoting partnerships between Huahui Health and leading local pharmaceutical companies. This initiative aims to encourage the local production of advanced biologics and the transfer of cutting-edge technology to Pakistan.
Hepatitis Delta, a severe liver-affecting virus, is increasingly becoming a serious health concern in Pakistan. The virus only causes disease in individuals already infected with Hepatitis B, making timely intervention and treatment critical.
